Results 161 to 170 of about 39,175 (290)
Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal +9 more
wiley +1 more source
Abstract Background Galectin‐3 (Gal‐3) is a circulating biomarker of fibrosis, with higher levels being associated with an increased risk of progression of heart failure and kidney disease. Patients with type 2 diabetes mellitus (T2DM) are at increased risk of both.
Paul M. Haller +12 more
wiley +1 more source
Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals [PDF]
N. P. Teli, Michael P. Timko
openalex +1 more source
Management of patients with heart failure at high risk of hyperkalaemia: The CARE‐HK in HF registry
Primary results of the CARE‐HK in HF registry. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; HK, hyperkalaemia; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; RASi,
Stephen J. Greene +24 more
wiley +1 more source
Control of biopharmaceutical properties of uricase by conjugation with dextran derivatives.
Yoshinobu Takakura +4 more
openalex +2 more sources
Characteristics of the late-stage biopharmaceutical pipeline [PDF]
Paul P Nagle +2 more
openalex +1 more source
Global patterns of polypharmacy after acute heart failure hospitalization. GDMT, guideline‐directed medical therapy; HF, heart failure. Aims Polypharmacy, defined as the concurrent use of ≥5 medications, is prevalent among older adults with heart failure (HF).
Wan Ting Tay +19 more
wiley +1 more source
Expression of concern: Flavin-adenine-dinucleotide gold complex nanoparticles: chemical modeling design, physico-chemical assessment and perspectives in nanomedicine. [PDF]
Arib C +6 more
europepmc +1 more source

